<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697775</url>
  </required_header>
  <id_info>
    <org_study_id>208129/028</org_study_id>
    <nct_id>NCT00697775</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents</brief_title>
  <official_title>Study to Assess the Feasibility of GSK Bio's Candidate HBV / MPL Vaccines Following Different Schedules and Formulations and to Compare Their Safety and Immunogenicity to That of Engerix™-B in Healthy Adolescents Aged 11 to 15</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      In this study the safety and immunogenicity of 2 different formulations of the candidate
      HBV-MPL vaccine administered according to a 0, 6-month schedule were explored and compared to
      that of Engerix™-B in healthy adolescents aged 11 to 15
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former
      name SmithKline Beecham
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <primary_completion_date type="Actual">May 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Serious adverse experiences (SAE)</measure>
    <time_frame>During the study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of solicited local and general symptoms</measure>
    <time_frame>During the 8-day follow-up period after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and causal relationship of unsolicited adverse events</measure>
    <time_frame>31-day follow-up period after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>At months 1, 2, 6, and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell mediated immunity</measure>
    <time_frame>At months 1, 6, and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV-MPL Formulation A at months 0 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV-MPL Formulation B at months 0 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV-MPL Formulation A at month 0 and Engerix™-B at month 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Engerix™-B at months 0, 1, 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-MPL vaccine Formulation A</intervention_name>
    <description>Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV-MPL vaccine Formulation B</intervention_name>
    <description>2-dose intramuscular injection</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B</intervention_name>
    <description>Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: between 11 and 15 years at the time of the first vaccination.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Written informed consent obtained from the parents or guardians of the subject and
             from the subject himself/herself in all subjects 15 years of age.

          -  If the subject is female, she must be of non-childbearing potential, if of
             childbearing potential, she must be abstinent or have used an adequate contraceptive
             for one month prior to vaccination, have a negative pregnancy test and must agree to
             continue such precautions for two months after completion of the vaccination series

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) during the study period or within 30 days preceding the first dose of study
             vaccine.

          -  Administration of chronic (defined as more than 14 days) immunosuppressants or other
             immune-modifying drugs within six months of vaccination.

          -  Planned administration of a vaccine not foreseen by the study protocol during the
             period starting from one week before each dose of vaccine and ending 30 days after.

          -  Previous vaccination against hepatitis B virus.

          -  Previous vaccination with vaccine containing MPL.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Acute disease at the time of enrollment.

          -  Hepatomegaly, right upper quadrant abdominal pain or tenderness.

          -  Axillary temperature of ≥ 37.5° C.

          -  Administration of immunoglobulin and / or any blood product within the six months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant or lactating female.

          -  History of chronic disease deemed by the investigator to be relevant.

          -  Positive for anti-HBV antibodies at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <last_update_submitted>June 13, 2008</last_update_submitted>
  <last_update_submitted_qc>June 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Isabelle Harpigny</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Recombinant hepatitis B vaccine</keyword>
  <keyword>Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

